['relapsed multiple myeloma', 'end-stage renal disease']
['carfilzomib']

        Key Inclusion Criteria:

          1. Relapsed multiple myeloma

          2. Evaluable disease (serum protein electrophoresis [SPEP]/urine protein electrophoresis
             [UPEP]/serum free light chain [SFLC] criteria)

          3. Received at least 1 prior treatment regimen or line of therapy for multiple myeloma

          4. End-stage renal disease (ESRD) on hemodialysis or CrCl ≥ 75 mL/min

          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2

          6. Adequate organ and bone marrow function

          7. Active congestive heart failure (New York Heart Association [NYHA] Class III to IV),
             symptomatic ischemia, conduction abnormalities uncontrolled by conventional
             intervention or myocardial infarction within the protocol-specified period prior to
             enrollment

        Key Exclusion Criteria:

          1. Immunoglobulin M (IgM) multiple myeloma

          2. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
             skin changes)

          3. Waldenström Macroglobulinemia

          4. Active congestive heart failure (NYHA Class III-IV) ischemia, conduction abnormalities

          5. Known human immunodeficiency virus (HIV), recent hepatitis B virus (HBV), hepatitis C
             virus (HCV)

          6. Myelodysplastic Syndrome

          7. Contraindication to test article, constituents, or required concomitant medications

          8. Other investigational drugs
      